ReviewFrontiers in oncology2026

Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework.

İbrahim Yıldız et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.